Targeting DNA damage response pathways in cancer
FJ Groelly, M Fawkes, RA Dagg, AN Blackford… - Nature Reviews …, 2023 - nature.com
Cells have evolved a complex network of biochemical pathways, collectively known as the
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes
PURPOSE Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved
for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic …
for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic …
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase …
Background Metastatic castration-resistant prostate cancer is enriched in DNA damage
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …
PARP and PARG inhibitors in cancer treatment
D Slade - Genes & development, 2020 - genesdev.cshlp.org
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …
genomic instability through radiotherapy and chemotherapy has been a powerful but …
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …
[HTML][HTML] A decade of clinical development of PARP inhibitors in perspective
Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …
[HTML][HTML] ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
Background Homologous recombination repair deficiency (HRD) is a frequent feature of
high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is …
high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is …
Leveraging the replication stress response to optimize cancer therapy
E Cybulla, A Vindigni - Nature Reviews Cancer, 2023 - nature.com
High-fidelity DNA replication is critical for the faithful transmission of genetic information to
daughter cells. Following genotoxic stress, specialized DNA damage tolerance pathways …
daughter cells. Following genotoxic stress, specialized DNA damage tolerance pathways …
PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells
SM Noordermeer, H van Attikum - Trends in cell biology, 2019 - cell.com
Poly-(ADP)-ribose polymerase (PARP) inhibition is synthetic lethal with deficiency for
homologous recombination (HR), a pathway essential for DNA double-strand break repair …
homologous recombination (HR), a pathway essential for DNA double-strand break repair …